Recent years have seen progress in treating brain disease, but one major challenge remains: getting therapeutic treatments across the blood-brain barrier. Now, Cranius LLC has raised $19.4 million to advance a device designed to bypass the blood-brain barrier and deliver medicines directly and continuously to the brain.

Cionic Inc. doubled its funding to date with a $12.5 million series A round led by Bluerun Ventures. The cash infusion will support the manufacturing and delivery of the company’s Neural Sleeve, development of additional products on its human augmentation platform and expansion of the team. The Neural Sleeve received FDA clearance in February and is designed to help individuals with impairments caused by multiple sclerosis, stroke, cerebral palsy and other diseases retain or regain mobility.

Delphinus Medical Technologies Inc. raised $30.4 million in a series D fundraising round to support worldwide commercialization of its Softvue 3D whole breast ultrasound tomography system. Both new and existing investors kicked in funds including Arboretum Ventures, Beringea, North Coast Technology Investors, Venture Investors, Hopen Life Science Ventures and Waycross Ventures.

Otolith Sound Inc. closed a $20 million series A financing round led by Morningside Ventures for its treatment for chronic vertigo. The latest funding follows a $3.3 million seed financing round and breakthrough device designation in June 2021. The funding will be used to support ongoing clinical programs and its anticipated FDA approval of its noninvasive wearable device Vestibular System Masking (nVSM) technology.

Life science startup Surge Inc. raised $2.6 million in a financing led by Hcvd and Boutique Venture Partners. The funds will be used to advance its artificial intelligence (AI)-powered technology aimed at making a patient’s surgical journey safer.

Following on a trifecta of regulatory wins, Optellum Ltd. raised $14 million in a series A funding round to commercialize its artificial intelligence (AI)-enabled lung cancer diagnostic platform. Optellum’s Virtual Nodule Clinic, which helps physicians identify and monitor patients at-risk of lung cancer, has received U.S. FDA clearance, CE-MDR in the European Union and UKCA in the U.K.